Oral Ozempic Reformulation Released for Type 2 Diabetes
A reformulated oral Ozempic tablet is now available for type 2 diabetes, offering a new daily pill option with lower doses.
A reformulated oral tablet version of Ozempic is now available for adults with type 2 diabetes. This new daily pill, released by Novo Nordisk, replaces the previous Rybelsus oral medication.
The new Ozempic pill comes in 1. 5 mg, 4 mg, and 9 mg doses, which are lower than the previous Rybelsus doses.
Officials state the reformulated pill maintains the same efficacy and safety profile as the original formulation.
This release follows the FDA's approval of other GLP-1 medications in oral form this year, including an oral Wegovy for weight management. Another oral GLP-1, Foundayo, was approved with a requirement for further study on potential risks.
Novo Nordisk anticipates a decision on a 25 mg Ozempic tablet dose by late 2026. The availability of both oral and injectable forms offers additional treatment options for patients with type 2 diabetes.
More stories
- Donor-specific genomes reveal 1,790 chromatin hotspots
- Ant genomes point to mobile DNA as size driver
- Strength-focused exercise after 50 reframes heart plans
- Flu visits double as early season puts vaccines in focus
- Hurricane Isaias halts Gulf output; US approves oil relief
- Unduliner reaches 0.897 accuracy in cancer-genome preprint
- Type 2 Diabetes: Blood Sugar Management
- GLP-1 Medications: Emerging Side Effects and Data Limitations
Latest news
- Bandai Namco sets 2027 cross-play test for Sparking Zero
- Washington weighs a harder bargain for Israel’s next defense aid pact
- Turkey-Israel spat puts Washington’s Gaza diplomacy in a tighter corner
- Bangladesh MICS7 shows high lead in 38.5% of children
- Mashreq CEO Abdelaal joins 15-member Swift board
- Sudan strikes kill 112, rights group says
- Ticketory says six-month bookings exceed €550,000
- Deadlock’s Solomon hides 8-to-32 chess reload boards